APA (7th ed.) Citation

L, S., C, W., C, B., P, B., M, G., & S, M. (2022). Clinical trial and postmarketing safety experience with MenACWY-TT, a meningococcal group A, C, W, and Y tetanus conjugate vaccine. Vaccine, 40(49), 7014. https://doi.org/10.1016/j.vaccine.2022.09.077

Chicago Style (17th ed.) Citation

L, Serra, Webber C, Burman C, Bueti P, Gorruso M, and Mather S. "Clinical Trial and Postmarketing Safety Experience with MenACWY-TT, a Meningococcal Group A, C, W, and Y Tetanus Conjugate Vaccine." Vaccine 40, no. 49 (2022): 7014. https://doi.org/10.1016/j.vaccine.2022.09.077.

MLA (9th ed.) Citation

L, Serra, et al. "Clinical Trial and Postmarketing Safety Experience with MenACWY-TT, a Meningococcal Group A, C, W, and Y Tetanus Conjugate Vaccine." Vaccine, vol. 40, no. 49, 2022, p. 7014, https://doi.org/10.1016/j.vaccine.2022.09.077.